Stockscreener 앱 받기
0.1741
2.96%
0.005
시간 외 거래:
.18
0.0059
+3.39%
전일 마감가:
$0.1691
열려 있는:
$0.1652
하루 거래량:
506.39K
Relative Volume:
0.48
시가총액:
$5.23M
수익:
$2.47M
순이익/손실:
$-24.73M
주가수익비율:
-0.0413
EPS:
-4.213
순현금흐름:
$-20.36M
1주 성능:
-3.33%
1개월 성능:
-29.51%
6개월 성능:
-93.95%
1년 성능:
-97.95%
1일 변동 폭
$0.1652
$0.1783
1주일 범위
$0.1564
$0.1819
52주 변동 폭
$0.1564
$9.60
VolitionRX Ltd Stock (VNRX) Company Profile
명칭
VolitionRX Ltd
전화
646 650 1351
주소
No. 24-05 Shaw Centre, 1 Scotts Road, Singapore, TX
Compare VNRX vs ABT, MDT, SYK, BSX, EW
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
VNRX
VolitionRX Ltd
|
0.1741 | 5.23M | 2.47M | -24.73M | -20.36M | -4.213 |
ABT
Abbott Laboratories
|
103.70 | 179.44B | 46.59B | 5.41B | 7.38B | 3.0938 |
MDT
Medtronic Plc
|
95.41 | 122.04B | 36.36B | 4.84B | 5.43B | 3.7261 |
SYK
Stryker Corp
|
307.15 | 117.81B | 25.27B | 3.34B | 4.57B | 8.6334 |
BSX
Boston Scientific Corp
|
45.69 | 66.22B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
89.07 | 51.34B | 6.30B | 1.07B | 1.09B | 1.8406 |
VolitionRX Ltd Stock (VNRX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-04-08 | 개시 | H.C. Wainwright | Buy |
| 2023-02-01 | 다운그레이드 | The Benchmark Company | Buy → Hold |
| 2022-02-17 | 재개 | Cantor Fitzgerald | Overweight |
| 2021-03-10 | 개시 | Cantor Fitzgerald | Overweight |
| 2018-05-16 | 개시 | Maxim Group | Buy |
| 2018-05-14 | 재확인 | The Benchmark Company | Buy |
| 2016-09-07 | 재확인 | Rodman & Renshaw | Buy |
| 2016-02-01 | 개시 | Rodman & Renshaw | Buy |
모두보기
VolitionRX Ltd 주식(VNRX)의 최신 뉴스
Nasdaq cuts target for VolitionRx stock to USD 13.89 from USD 16.83 - AD HOC NEWS
Neither party sold shares as VolitionRx (VNRX) retained 284 shares for its commercial chief’s taxes. - Stock Titan
No shares were sold as VolitionRx (VNRX) retained 608 COO shares for cancellation to cover taxes. - Stock Titan
VolitionRx stock faces a data driven trading reset - AD HOC NEWS
Lagoda Investment Management, L.P. Trims VolitionRX Ltd (VNRX) S - GuruFocus
VolitionRx Limited stock edges higher as investors weigh recent results - AD HOC NEWS
VolitionRx Limited Shares Further Details On The Official Launch Of The DETECSEPS Project On The Early Detection Of Sepsis - marketscreener.com
VolitionRx joins France sepsis detection consortium By Investing.com - Investing.com Nigeria
VolitionRx Shares Further Details and Video of the DETECSEPS Program Launch in France - PR Newswire
VolitionRx Participates in Launch of DETECSEPS Program in France - PR Newswire
A €6.3 million French program will test one blood marker to spot sepsis early - Stock Titan
VolitionRx Shares Further Details and Video of the DETECSEPS Program Launch in France - Nasdaq
One manager now reports nearly 6% of VolitionRx (NYSE: VNRX) - Stock Titan
VolitionRx Limited (AMEX:VNRX) Prepays $7.5M Convertible Note, Cuts Dilution Risk - TradingView
VolitionRx Limited Announces Pre-Payment in Full of $7.5 million Senior Secured Convertible Promissory Note Due May 20, 2027 - Yahoo Finance
VNRX: VolitionRx Prepays Outstanding Balance on the $7,500,000 Lind Senior Secured Convertible Promissory Note Dated May 20, 2025. Review of Papers, Posters, and Videos Released in Mid-2026. Sysmex Collaboration is the 3rd Recent Agreement in t - Yahoo Finance
VolitionRX Limited Announces Pre-Payment in F - Moomoo
VOLITIONRX LTD SEC Filing (Sep 11, 2026) - Stock Titan
Lagoda Investment Management, L.P. Adds VolitionRX Ltd (VNRX) -- Shares Look 98% Undervalued on GF Value - GuruFocus
VNRX Looks 98.1% Undervalued on GF Value™ Despite Financial Dist - GuruFocus
A blood-based method detected 95% of stage I and II cancers. - Stock Titan
Dilution risk flagged as VolitionRx (NYSE: VNRX) registers more Lind shares for resale - Stock Titan
VolitionRx (NYSE: VNRX) details Lind note and warrant stake under 4.99% cap - Stock Titan
Lagoda Investment Management Elevates VOLITIONRX LTD (AMEX: VNRX) Stake to Activist 13D Filing at 7.4% - kalkinemedia.com
VNRX - Finviz
Fatima Dickey Pushes for Changes at VolitionRx with 7.4% Stake - tradingview.com
$11M VolitionRx (VNRX) stake comes with call to cut executive pay - Stock Titan
VolitionRx Removes $10M Annual Cap on ATM Sales Via Lind Waiver - Minichart
$VolitionRX (VNRX.US)$ it be like that. not even tripping cuz! - Moomoo
VolitionRx Files for Secondary Offering of Common Shares - Moomoo
This $21 Stock Has CRAZY Potential Baby Sleep (NynJ4YJi1C) - mshale.com
Nasdaq Surges 200 Points; Nvidia Posts Upbeat Q2 Results - Sahm
VolitionRx Files for Secondary Offering of Common Shares - Yahoo Finance
Penny Stock VolitionRx Expands Addressable Markets With Key Diagnostic Validations - Benzinga
$VolitionRX (VNRX.US)$ - Moomoo
Penny Stock VolitionRx Expands Addressable Markets With Key Diagnostic Validations - Yahoo Finance
VolitionRx revenue rises 112% in H1FY26; shares surge 100% - scanx.trade
VolitionRx Highlights Commercial Momentum and Multi-Pillar Execution Across $27+ Billion Total Addressable Markets - Yahoo Finance
Volition's sepsis biomarker predicts 28-day death and kidney treatment needs - Stock Titan
VNRX Looks 97.8% Undervalued on GF Value™ - GuruFocus
VolitionRX Ltd (VNRX) (Q2 2026) Earnings Call Highlights: Strate - GuruFocus
Benchmark reiterates Hold on VolitionRX stock amid cost cuts - Investing.com
Benchmark reiterates Hold on VolitionRX stock amid cost cuts By Investing.com - Investing.com Canada
Benchmark reiterates Hold on VolitionRX stock amid cost cuts By Investing.com - Investing.com India
VNRX Looks 97.6% Undervalued on GF Value™ - GuruFocus
Lagoda Investment discloses 14.0% VolitionRX (VNRX) stake in amended Schedule 13G - Stock Titan
Teleconferência de Resultados do 2º Trimestre de 2026 da VolitionRx (VNRX): Custos Caem à Medida que o Pipeline Nu.Q Avança - TradingKey
Conferencia de resultados del Q2 de 2026 de VolitionRx (VNRX): los costos caen a medida que avanza la cartera de desarrollo de Nu.Q - TradingKey
VolitionRx (VNRX) Q2 2026 Ergebniskonferenz: Kosten sinken bei Fortschritten der Nu.Q-Pipeline - TradingKey
Volitionrx Ltd earnings beat by $0.06, revenue fell short of estimates - Investing.com Canada
VolitionRX Ltd (VNRX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
VolitionRX Ltd 주식 (VNRX) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Reynolds Cameron John | President and CEO |
Oct 14 '25 |
Buy |
0.51 |
110,000 |
56,100 |
2,534,847 |
| Innes Guy Archibald | Director |
Oct 14 '25 |
Buy |
0.51 |
96,153 |
49,038 |
1,062,967 |
| STILL TIMOTHY I | Director |
Oct 14 '25 |
Buy |
0.51 |
48,076 |
24,519 |
1,535,458 |
5.64%
1.00%
자본화:
|
볼륨(24시간):